SUPPLEMENTAL INFORMATION (Tables)

12 Months Ended

Dec. 31, 2017

SUPPLEMENTAL INFORMATION

Schedule of revenue by geographic area

	Year ended December 31, 2017		Year ended December 31, 2016
Licensing Revenue:
Europe	$	1,065	$	1,065
Total revenue	$	1,065	$	1,065

Schedule of long-lived assets by entities

	December 31,
	2017		2016
Long-lived assets:
SteadyMed Ltd.	$	5,213	$	4,455
SteadyMed Therapeutics, Inc.		94		94
Total long-lived assets	$	5,307	$	4,549

Schedule of sales to single customer exceeding 10%

	Year ended December 31, 2017			Year ended December 31, 2016
Sales to a single customer exceeding 10%:
Cardiome		100	%		100	%

Schedule of financial expense (income), net

	Year ended December 31,
	2017			2016
Financial expenses:
Interest expense and bank fees	$	26		$	97
Reevaluation of fair value of warrants to purchase Ordinary Shares		2,448			—
Foreign currency translation adjustments		116			—
Issuance costs allocated to warrants		441			784
	$	3,031		$	881
Financial income:
Interest income	$	(267	)	$	(74	)
Reevaluation of fair value of warrants to purchase Ordinary Shares		—			(2,491	)
Foreign currency translation adjustments		—			(217	)
	$	(267	)	$	(2,782	)
Total financial income, net	$	2,764		$	(1,901	)

Schedule of net loss and weighted average number of shares

	Year ended December 31,
	2017		2016
Numerator:
Net loss	$	23,205	$	25,869
Net loss available to shareholders of Ordinary Shares	$	23,205	$	25,869
Denominator:
Weighted average number of Ordinary Shares used in computing basic and diluted net loss per share		24,421,288		16,253,975